Summary
A sensitive and specific high-pressure liquid chromatographic assay was developed to characterize the plasma elimination and urinary excretion of mitomycin C in humans. Extraction of mitomycin C and an internal standard, porfiromycin, from plasma by chromatography over a non-ionic resin, Porapak Q, yields high recovery of both compounds and facilitates measurement of as little as 5 ng mitomycin C by reversed-phase high-pressure liquid chromatography. The assay was used to characterize the plasma elimination of mitomycin C in rabbits and was shown to be applicable to the characterization of the pharmacokinetics of mitomycin C in humans receiving as little as 8 mg/m2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker LH, Vaitkevicius VK (1979) The development of an acute intermittent schedule — Mitomycin C. In: Carter SK, Crooke ST (eds) Mitomycin C: Current status and new developments. Academic Press, London, p 77
Baker LH, Izbicki RM, Vaitkevicius VK (1976) Phase II study of porfiromycin vs mitomycin C utilizing acute intermittent schedules. Med Pediatr Oncol 2:207
Fujita H (1971) Comparative studies on the blood level, tissue distribution, excretion and inactivation of anticancer drugs. Jpn J Clin Oncol 12:151
Frank W, Osterberg AE (1960) Mitomycin C (NSC 26980): An evaluation of the Japanese reports. Cancer Chemother Rep 9:114
Godfrey TE, Wilbur DW (1972) Clinical experience with mitomycin C in large infrequent doses. Cancer 29:1647
Gutierrez ML, Evans A, Rohrbaugh T, Belasco J, Lee FH, Crooke ST (1981) Phase II evaluation of mitomycin C (MMC) in children with refractory solid tumors using the single high intermittent dose schedule. Med Pediatr Oncol 9:405
Hata T, Hossenlopp C, Takita H (1961) Studies on mitomycin C, especially method of administration. Cancer Chemother Rep 13:67
Kenis Y, Stryckmans P (1964) Action de la mitomycin C dans 65 cas de tumeurs malignes. Comparaison de l'effet de doses faibles, répétées et de doses “massives”. Chemotherapia 8:114
Konits PH, Aisner J, van Echo DA, Lichtenfeld K, Wiernik PH (1981) Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 48:1295
Kono A, Hara Y, Eguchi S, Tanaki M, Matsushima Y (1979) Determination of mitomycin C in biomedical specimens by high performance liquid chromatography. J Chromatogr 164:404
Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30:562
Reich SD (1979) Clinical pharmacology of mitomycin C. In: Carter SK, Crooke ST (eds) Mitomycin C: Current status and new developments. Academic Press, London, p 243
Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile J, Crooke ST (1978) Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62:163
Schein PS, Macdonald JS, Hoth DF, Woolley PV (1979) The FAM (5-fluorouracil, adriamycin, mitomycin C) and SMF (streptozotocin, mitomycin C, 5-fluorouracil) chemotherapy regimens. In: Carter SK, Crooke ST (eds) Mitomycin C: Current status and new developments. Academic Press, London, p 133
Schwartz HS (1961) Pharmacology of mitomycin C. III. In vivo metabolism by rat liver. J Pharmacol Exp Ther 136:250
Srivastava SC, Hornemann U (1978) High-pressure liquid chromatography of the antibiotics mitomycin A, B, and C and of polar mitomycin C conversion products. J Chromatogr 161:393
Sutow WW, Wilbur JR, Vietti TJ, Vuthilhagdee P, Fujimoto T, Watanabe A (1971) An evaluation of dosage schedules of mitomycin C (NSC 26980) in children. Cancer Chemother Rep 55:285
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Hazel, G.A., Kovach, J.S. Pharmacokinetics of mitomycin C in rabbit and human. Cancer Chemother. Pharmacol. 8, 189–192 (1982). https://doi.org/10.1007/BF00255482
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255482